Characteristics in relation to demographic, disease related and clinical variables of a cohort of Parkinson’s disease patients from Northern Sri Lanka
Objective: To evaluate motor and non-motor domains, as well as for demographic and disease related characteristics of patients with Parkinson’s disease and the relations with…Effects of computerized cognitive training, with and without concurrent exercise, on executive functions in Parkinson’s disease
Objective: To explore the effect cognitive training group vs cognitive training with concurrent physical exercise group on executive functions in Parkinson's Disease. Background: PD patients…Study on Correlation between Serum Vitamin D Level and Cognition of Parkinson’s Disease
Objective: This article made an elaboration of the correlation between serum vitamin D and cognitive function of PD. Background: Recent years, studies have suggested that…MicroRNA expression misregulation in iPSC-derived dopaminergic neurons from sporadic and LRRK2-associated Parkinson disease patients
Objective: To investigate whether miRNA expression alterations occur in iPSC-derived DAn from sporadic PD (sPD) as well as monogenic LRRK2-associated PD patients. Background: MicroRNA (miRNA)…Resting state networks abnormalities among healthy LRRK2 mutation carriers
Objective: To assess the integrity of resting state networks in non-manifesting carriers of the G2019S mutation in the LRRK2 gene. Background: Non-manifesting first degree relatives…Lack of TMEM230 mutations in patients with familial and sporadic Parkinson’s disease in a Taiwanese population
Objective: To confirm the role of mutations in transmembrane protein 230 (TMEM230) in a large number of PD patients and controls in a Taiwanese population.…MicroRNAs as Biomarkers for Parkinson’s Disease
Objective: To identify potential biomarkers for Parkinson’s disease by evaluating miRNA in cerebrospinal fluid samples collected from PD and healthy control subjects. Background: The diagnosis…Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance of Anti Parkinson’s Therapy
Objective: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease worldwide, affecting more than 7 million people worldwide. However, treatment outcome in many patients…EEG microstates changes in response to increase in dopaminergic stimulation in treated typical Parkinson’s disease patients without clinical fluctuations
Objective: Neurotropic drugs may modulate Electroencephalography (EEG) microstates (MS), but there are no works showing EEG MS default-mode network changes in response to dopaminergic stimulation…Parkinson’s disease motor symptoms are linked to red nucleus volume and cerebellar metabolism
Objective: To investigate the involvement of the red nucleus (RN) and cerebellum in the motor symptoms of Parkinson's disease (PD). Background: Numerous studies have shown…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.